Advertisement
UK markets closed
  • FTSE 100

    7,895.85
    +18.80 (+0.24%)
     
  • FTSE 250

    19,391.30
    -59.37 (-0.31%)
     
  • AIM

    745.67
    +0.38 (+0.05%)
     
  • GBP/EUR

    1.1607
    -0.0076 (-0.65%)
     
  • GBP/USD

    1.2370
    -0.0068 (-0.55%)
     
  • Bitcoin GBP

    51,715.30
    +1,727.35 (+3.46%)
     
  • CMC Crypto 200

    1,371.97
    +59.34 (+4.52%)
     
  • S&P 500

    4,967.23
    -43.89 (-0.88%)
     
  • DOW

    37,986.40
    +211.02 (+0.56%)
     
  • CRUDE OIL

    83.24
    +0.51 (+0.62%)
     
  • GOLD FUTURES

    2,406.70
    +8.70 (+0.36%)
     
  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     
  • HANG SENG

    16,224.14
    -161.73 (-0.99%)
     
  • DAX

    17,737.36
    -100.04 (-0.56%)
     
  • CAC 40

    8,022.41
    -0.85 (-0.01%)
     

Bayer - more antitrust asset sales on the cards after BASF deal

FRANKFURT (Reuters) - Bayer (BAYGn.DE) said it expected antitrust authorities to make the planned acquisition of Monsanto (MON.N) conditional on more asset sales after agreeing to sell seed and herbicide businesses for 5.9 billion euro (£5.31 billion) to BASF (BASFn.DE).

"By no means did the deal that was signed with BASF constitute the totality of antitrust divestitures ... The agencies will render their verdict on what the necessary remedies are. It's probably a first step and somewhat more is to come," Chief Executive Werner Baumann told an analyst call on Thursday after the release of third-quarter results.

Earlier this month, European regulators pushed back the Jan. 22, 2018 deadline on the Monsanto approval process so that the companies can garner information they have been asked for.

Baumann said that a second such situation, known as "stop the clock", had emerged but he was hopeful the required data could very soon be provided to the European antitrust watchdog.

Bayer reiterated it was planning to wrap up the Monsanto deal in early 2018.

(Reporting by Ludwig Burger; Editing by Victoria Bryan)